Cell-free DNA Analysis of Chromosome Anomalies in Early Pregnancy Loss

NCT04935138 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 78

Last updated 2023-12-01

No results posted yet for this study

Summary

The study assesses the accuracy of cell-free DNA (cfDNA) analysis in detecting whole chromosomal aneuploidies from maternal plasma of patients with early, missed miscarriage.

Conditions

  • Early Pregnancy Loss

Interventions

GENETIC

cfDNA analysis

sequencing data from cfDNA analysis

Sponsors & Collaborators

  • Illumina, Inc.

    collaborator INDUSTRY
  • Quest Diagnostics-Nichols Insitute

    lead INDUSTRY

Principal Investigators

  • Pranoot X Tanpaiboon, MD · Quest Diagnostics-Nichols Insitute

  • Karen E Racicot, PhD · Quest Diagnostics-Nichols Insitute

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-01
Primary Completion
2022-12-31
Completion
2022-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04935138 on ClinicalTrials.gov